An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism

Int J Mol Sci. 2013 Nov 26;14(12):23289-96. doi: 10.3390/ijms141223289.

Abstract

Planaria are the simplest organisms with bilateral symmetry and a central nervous system (CNS) with cephalization; therefore, they could be useful as model organisms to investigate mechanistic aspects of parkinsonism and to screen potential therapeutic agents. Taking advantage of the organism's anti-tropism towards light, we measured a significantly reduced locomotor velocity in planaria after exposure to 3-iodo-L-tyrosine, an inhibitor of tyrosine hydroxylase that is an enzyme catalyzing the first and rate-limiting step in the biosynthesis of catecholamines. A simple semi-automatic assay using videotaped experiments and subsequent evaluation by tracking software was also implemented to increase throughput. The dopaminergic regulation of locomotor velocity was confirmed by bromocriptine, a drug whose mechanisms of action to treat Parkinson's disease is believed to be through the stimulation of nerves that control movement.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bromocriptine / chemistry
  • Bromocriptine / metabolism
  • Humans
  • Light
  • Locomotion / drug effects
  • Locomotion / radiation effects
  • Models, Animal
  • Monoiodotyrosine / chemistry
  • Monoiodotyrosine / metabolism
  • Parkinson Disease / enzymology
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Planarians / enzymology*
  • Protein Binding
  • Receptors, Dopamine / metabolism
  • Tyrosine 3-Monooxygenase / antagonists & inhibitors
  • Tyrosine 3-Monooxygenase / metabolism*

Substances

  • 3-iodotyrosine
  • Receptors, Dopamine
  • Bromocriptine
  • Tyrosine 3-Monooxygenase
  • Monoiodotyrosine